Oral selinexor–dexamethasone for triple-class refractory multiple myeloma

Authors

Ravi Vij, Washington University School of Medicine in St. Louis
et al.

Journal

The New England Journal of Medicine

Publication Date

2019

Volume

381

Issue

8

First Page

727

Last Page

738

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1903455

Rights and Permissions

Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., . . . Jagannath, S. (2019). Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 381(8), 727-738. doi:10.1056/NEJMoa1903455 Copyright © 2019 Massachusetts Medical Society. All rights reserved. https://www.nejm.org/doi/full/10.1056/NEJMoa1903455

Recommended Citation

Vij, Ravi and al., et, "Oral selinexor–dexamethasone for triple-class refractory multiple myeloma." The New England Journal of Medicine. 381, 8. 727 - 738. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8107